Yale-New Haven Medical Center Hematology and Medical Oncology

Topics

• Acute Myeloid Leukemia Research 322
• Cancer Immunotherapy and Biomarkers 282
• Multiple Myeloma Research and Treatments 224
• Breast Cancer Treatment Studies 222
• CAR-T cell therapy research 152
• Hematopoietic Stem Cell Transplantation 150
• Cancer Treatment and Pharmacology 142
• Lymphoma Diagnosis and Treatment 136
• Hepatocellular Carcinoma Treatment and Prognosis 129
• Brain Metastases and Treatment 124
• HER2/EGFR in Cancer Research 115
• Lung Cancer Treatments and Mutations 99

Most cited

1. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 1,452 citations · Jill Lacy

2. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

   NEJM evidence · 2022 · 1,418 citations · Ghassan Abou-Alfa

3. Gastric cancer.

   Lancet (London, England) · 2025 · 309 citations · Raghav Sundar

4. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

   Lancet (London, England) · 2024 · 686 citations · Thuy Tran

5. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

   The Lancet. Oncology · 2022 · 997 citations · Ghassan Abou-Alfa

6. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.

   Clinical and molecular hepatology · 2025 · 254 citations · Ghassan Abou-Alfa

7. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

   The New England journal of medicine · 2023 · 739 citations · Kim Margolin

8. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 501 citations · Jill Lacy